18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.
Thorsten DerlinChristian Schultze-FloreyRudolf A WernerNora MöhnThomas SkripuletzSascha DavidGernot BeutelMatthias EderTobias L RossFrank M BengelArnold GanserChristian KoeneckePublished in: Annals of nuclear medicine (2020)
Early metabolic changes in lymphoma lesions and off-target lymphoid organs parallel medium-term response to CAR-T-cell therapy. PET can identify patients at risk for severe toxicity.
Keyphrases
- diffuse large b cell lymphoma
- cell therapy
- epstein barr virus
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- stem cells
- computed tomography
- acute myeloid leukemia
- oxidative stress
- peritoneal dialysis
- preterm infants
- acute lymphoblastic leukemia
- prognostic factors
- early onset
- positron emission tomography
- cancer therapy
- drug delivery
- bone marrow
- multiple myeloma
- drug induced
- preterm birth